



# Sample Plan Review

Date: Jan 2024 - Dec 2024





# Agenda

1. Liviniti Value
2. Plan Performance
3. Member Utilization
4. Clinical Overview
5. Specialty
6. Variable Copay
7. Metrics by Location and Plan

# Liviniti Value

# Overall Savings

	Current Period Jan 2024 - Dec 2024	Prior Period Jan 2023 - Dec 2023
Network	\$21,753	\$20,787
SavePlus Member Savings*	\$2,448	N/A
SavePlus Plan Savings*	\$0	N/A
Rebates**	\$157,004	\$106,434
Clinical	\$159,757	\$111,216
Avoided Fees	\$9,190	\$9,773
Variable Copay	\$81,221	\$49,541
<b>Total Savings</b>	<b>\$431,373</b>	<b>\$297,751</b>



# Variable Copay Savings Overview

## Total Savings

### Current Period

Jan 2024 - Dec 2024


**\$81,221**

### Prior Period

Jan 2023 - Dec 2023

**\$49,541**

## What is driving savings?




Top 5 Therapeutic Classes	# of Drugs	Savings
Analgesics - Anti-Inflammatory	2	\$45,726
Anticoagulants	1	\$22,362
Cardiovascular Agents - Misc.	1	\$4,327
Migraine Products	2	\$4,198
Antidiabetics	9	\$4,123
<b>Total</b>	<b>15</b>	<b>\$80,736</b>


# Cost and Utilization Summary

Jan 2024 - Dec 2024

## Claims




## Plan Paid



# Plan Performance

# Plan Paid by Drug Type Overview



# Executive Summary

Current Period: Jan 2024 - Dec 2024 | Prior Period: Jan 2023 - Dec 2023

	Current Period	Prior Period	Variance
Generic Plan Paid	\$73,368	\$59,045	24.3%
Brand Plan Paid	\$239,481	\$139,955	71.1%
Specialty Plan Paid	\$292,377	\$194,493	50.3%
Total Plan Paid	\$605,226	\$393,493	53.8%

Average Members	Utilizing Members
384	65.8%
Prior      Variance	Prior      Variance
365      5.2%	67.3%      -2.2%
Total Paid Claims	Plan Paid PMPM
3,554	\$131
Prior      Variance	Prior      Variance
4,087      -13.0%	\$90      46.2%

# Pharmacy Spend Analysis

	Current Period Jan 2024 - Dec 2024	Prior Period Jan 2023 - Dec 2023	Variance
<b>Total Paid Claim Count</b>	3,554	4,087	-13.0%
Generic Dispensing Rate	89.2%	88.7%	0.6%
Generic Plan Paid	\$73,368	\$59,045	24.3%
Generic Plan Paid %	12.1%	15.0%	-19.3%
Brand Dispensing Rate	9.3%	10.5%	-11.4%
Brand Plan Paid	\$239,481	\$139,955	71.1%
Brand Plan Paid %	39.6%	35.6%	11.2%
Specialty Plan Paid	\$292,377	\$194,493	50.3%
Specialty Cost Driven by (X) Members	9	5	80.0%
Specialty Utilization (Members) %	3.6%	2.0%	80.0%
Specialty Plan Paid %	48.3%	49.4%	-2.2%
<b>Total</b>	<b>\$605,226</b>	<b>\$393,493</b>	<b>53.8%</b>

# Claims By Distribution Channel

	Current Period Jan 2024 - Dec 2024			Prior Period Jan 2023 - Dec 2023		
	Plan Paid	Claims	Unique Claimants	Plan Paid	Claims	Unique Claimants
<b>First Choice Network Claims</b>	\$567,159	2,582	211	\$357,790	3,166	204
30 Day Prescriptions	\$371,362	1,215	205	\$301,687	2,462	202
90 Day Prescriptions	\$195,797	1,367	126	\$56,102	704	107
<b>Non-First Choice Network Claims</b>	\$27,204	882	66	\$26,355	831	68
<b>Mail Order Claims</b>	\$10,863	90	3	\$9,348	90	5
<b>Total</b>	\$605,226	3,554	253*	\$393,493	4,087	246*

\*Total Unique Claimants are calculated across all claims for the requested time frame.




# Member Utilization

# Member Cost Trends


■ Current Period: Jan 2024 - Dec 2024

■ Prior Period: Jan 2023 - Dec 2023


## Plan Cost




## Average Age




## Plan Paid /Claims



## Percent of Spend




## Total Claims



# Clinical Overview

# Top Therapeutic Classes by Plan Paid

\*Up to ten entries are displayed below



# Top Specialty Drugs By Plan Paid

Jan 2024 - Dec 2024

\*Up to ten entries are displayed below.

Prior Rank	Current Rank	Drug Name	Therapy Class	Prior Plan Paid	Current Plan Paid	Prior Claims	Current Claims	Prior Unique Members	Current Unique Members	Prior % of Total Cost	Current % of Total Cost
1	1	Rinvoq	Analgesics - Anti-Inflammatory	\$108,351	\$161,544	19	28	2	3	27.5%	26.7%
N/A	2	Brukina	Antineoplastics And Adjunctive Therapies	N/A	\$88,959	N/A	6	N/A	1	N/A	14.7%
2	3	Enbrel SureClick	Analgesics - Anti-Inflammatory	\$86,142	\$19,075	13	3	1	1	21.9%	3.2%
3	4	Skyrizi Pen	Dermatologicals	N/A	\$13,674	N/A	1	1	1	N/A	2.3%
N/A	5	Vivitrol	Antidotes And Specific Antagonists	N/A	\$4,845	N/A	3	N/A	1	N/A	0.8%
N/A	6	Adbry	Dermatologicals	N/A	\$3,838	N/A	2	N/A	1	N/A	0.6%
N/A	7	Mercaptopurine	Antineoplastics And Adjunctive Therapies	N/A	\$444	N/A	9	N/A	1	N/A	0.1%
All Others				N/A	N/A	N/A	N/A	1	N/A	N/A	N/A
Total				\$194,493	\$292,377	32	52	5*	9*	49.4%	48.3%

\*Total Unique Members are calculated across all claims for this slide's category for the requested time frame.

# Top Brand Drugs (non-specialty) By Plan Paid

Jan 2024 - Dec 2024

\*Up to ten entries are displayed below.

Prior Rank	Current Rank	Drug Name	Therapy Class	Prior Plan Paid	Current Plan Paid	Prior Claims	Current Claims	Prior Unique Members	Current Unique Members	Prior % of Total Cost	Current % of Total Cost
51	1	Brukinsa	Antineoplastics And Adjunctive Therapies	N/A	\$77,424	N/A	6	1	1	N/A	12.8%
1	2	Jardiance	Antidiabetics	\$21,951	\$42,461	36	47	5	6	5.6%	7.0%
3	3	Eliquis	Anticoagulants	\$14,277	\$22,576	69	35	8	9	3.6%	3.7%
4	4	Trulicity	Antidiabetics	\$13,865	\$10,436	13	4	1	1	3.5%	1.7%
N/A	5	Mounjaro	Antidiabetics	N/A	\$8,213	N/A	9	N/A	2	N/A	1.4%
N/A	6	Biktarvy	Antivirals	N/A	\$6,231	N/A	2	N/A	1	N/A	1.0%
21	7	Emgality	Migraine Products	\$803	\$5,465	5	15	1	1	0.2%	0.9%
2	8	Trelegy Ellipta	Antiasthmatic And Bronchodilator Agents	\$18,327	\$5,389	32	7	4	2	4.7%	0.9%
11	9	Entresto	Cardiovascular Agents - Misc.	\$3,902	\$5,339	17	14	2	2	1.0%	0.9%
N/A	10	Omnipod 5 DexG7G6 Pods Gen 5	Medical Devices And Supplies	N/A	\$4,733	N/A	10	N/A	2	N/A	0.8%
All Others				\$66,830	\$51,214	256	183	76	59	17.0%	8.5%
Total				\$139,955	\$239,481	428	332	86*	69*	35.6%	39.6%

\*Total Unique Members are calculated across all claims for this slide's category for the requested time frame.

# Top Generic Drugs (non-specialty) By Plan Paid

Jan 2024 - Dec 2024

\*Up to ten entries are displayed below.

Prior Rank	Current Rank	Drug Name	Therapy Class	Prior Plan Paid	Current Plan Paid	Prior Claims	Current Claims	Prior Unique Members	Current Unique Members	Prior % of Total Cost	Current % of Total Cost
8	1	Fluticasone Furoate-Vilanterol	Antiasthmatic And Bronchodilator Agents	\$1,875	\$6,589	7	25	1	3	0.5%	1.1%
2	2	Dofetilide	Antiarrhythmics	\$3,800	\$5,141	22	23	2	2	1.0%	0.8%
4	3	Budesonide-Formoterol Fumarate	Antiasthmatic And Bronchodilator Agents	\$3,368	\$4,607	14	20	2	4	0.9%	0.8%
1	4	Atorvastatin Calcium	Antihyperlipidemics	\$5,312	\$2,988	248	181	33	34	1.4%	0.5%
7	5	Metoprolol Succinate ER	Beta Blockers	\$2,584	\$2,506	163	127	21	27	0.7%	0.4%
5	6	Albuterol Sulfate HFA	Antiasthmatic And Bronchodilator Agents	\$2,768	\$2,097	63	64	25	26	0.7%	0.3%
3	7	Fluticasone-Salmeterol	Antiasthmatic And Bronchodilator Agents	\$3,586	\$1,799	13	10	4	4	0.9%	0.3%
N/A	8	Insulin Degludec FlexTouch	Antidiabetics	N/A	\$1,711	N/A	11	N/A	1	N/A	0.3%
13	9	Flecainide Acetate	Antiarrhythmics	\$1,015	\$1,636	26	20	3	3	0.3%	0.3%
11	10	Rosuvastatin Calcium	Antihyperlipidemics	\$1,391	\$1,550	96	70	22	21	0.4%	0.3%
All Others				\$33,345	\$42,743	2,975	2,619	230	238	8.5%	7.1%
Total				\$59,045	\$73,368	3,627	3,170	236*	243*	15.0%	12.1%

\*Total Unique Members are calculated across all claims for this slide's category for the requested time frame.



# Top GLP-1 Drugs by Plan Paid

Jan 2024 - Dec 2024

\*Up to ten entries are displayed below.

Current Rank	Drug Name	Therapy Class	Plan Paid	Claims	Unique Members	% of Total Plan Cost
1	Trulicity	Antidiabetics	\$10,436	4	1	1.7%
2	Mounjaro	Antidiabetics	\$8,213	9	2	1.4%
3	Ozempic (1 MG/DOSE)	Antidiabetics	\$3,489	2	1	0.6%
4	Ozempic (2 MG/DOSE)	Antidiabetics	\$2,360	3	2	0.4%
5	Ozempic (0.25 or 0.5 MG/DOSE)	Antidiabetics	\$2,209	5	2	0.4%
Total			\$26,707	23	05*	4.4%


**4.4%**  
of Total Plan Cost

\*Total Unique Members are calculated across all claims for this slide's category for the requested time frame.

# Specialty

# Specialty Overview


## Specialty Plan Paid




# Variable Copay

# Top Drugs and Therapeutic Classes Filled through VCP

## Top Drugs Filled through VCP



## Top Therapeutic Classes Filled through VCP



# Variable Copay Savings - Top Drugs

Jan 2024 - Dec 2024

\*Up to ten entries are displayed below.

Drug Name	Copay w/Coupon	Unique Members	Claims	Savings per Claim	Total Savings
Rinvoq	\$9,249	2	6	\$7,434	\$44,606
Eliquis	\$12,679	4	18	\$1,242	\$22,362
Entresto	\$60	2	6	\$721	\$4,327
Emgality	\$1,677	1	13	\$251	\$3,264
Synjardy XR	\$100	1	10	\$175	\$1,750
Enbrel SureClick	\$1,660	1	3	\$373	\$1,120
Nurtec	\$41	1	1	\$934	\$934
Ozempic (0.25 or 0.5 MG/DOSE)	\$1,578	2	4	\$219	\$875
Ozempic (1 MG/DOSE)	\$50	1	2	\$271	\$542
Trelegy Ellipta	\$0	1	2	\$242	\$484
All Other	\$2,846	3	13	\$74	\$956
<b>Total</b>	<b>\$29,940</b>	<b>15*</b>	<b>78</b>	<b>\$11,936</b>	<b>\$81,220</b>

## Total Savings - All Drugs

Current Period  
Jan 2024 - Dec 2024 **\$81,221**

Prior Period  
Jan 2023 - Dec 2023 **\$49,541**

## Total Claims

**78**

\*Total Unique Members are calculated across all claims for this slide's category for the requested time frame.

# Variable Copay Savings - Top Therapeutic Classes

Jan 2024 - Dec 2024

\*Up to ten entries are displayed below.

Therapeutic Class	Copay w/Coupon	Unique Members	Claims	Savings per Claim	Total Savings
Analgesics - Anti-Inflammatory	\$10,909	3	9	\$5,081	\$45,726
Anticoagulants	\$12,679	4	18	\$1,242	\$22,362
Cardiovascular Agents - Misc.	\$60	2	6	\$721	\$4,327
Migraine Products	\$1,718	1	14	\$300	\$4,198
Antidiabetics	\$4,573	6	26	\$159	\$4,123
Antiasthmatic And Bronchodilator Agents	\$0	2	2	\$242	\$484
Antiarrhythmics	\$0	1	1	\$0	\$0
Antihyperlipidemics	\$0	1	0	\$0	\$0
Beta Blockers	\$0	1	2	\$0	\$0
Gastrointestinal Agents - Misc.	\$0	1	0	\$0	\$0
All Other		0			
<b>Total</b>	<b>\$29,939</b>	<b>15*</b>	<b>78</b>	<b>\$7,745</b>	<b>\$81,220</b>

\*Total Unique Members are calculated across all claims for this slide's category for the requested time frame.



# Metrics by Location and Plan

# Metrics by Employee Location Code

Jan 2024 - Dec 2024

Current Rank	Employee Location Code	Plan Paid	Specialty Plan Paid	Brand Plan Paid	Generic Plan Paid	Claims	Unique Members
1	00203A	\$432,434	\$214,163	\$173,267	\$45,003	1,893	101
2	00202A	\$149,468	\$78,214	\$48,448	\$22,807	1,359	138
3	00303A	\$14,712	\$0	\$11,270	\$3,443	128	8
4	00103A	\$8,612	\$0	\$6,497	\$2,115	168	5
5	00103C	\$0	\$0	\$0	\$0	5	1
6	00302A	\$0	\$0	\$0	\$0	1	1
Total		\$605,226	\$292,377	\$239,481	\$73,368	3,554	253*

\*Total Unique Members are calculated across all claims for this slide's category for the requested time frame.

# Metrics by Plan

Jan 2024 - Dec 2024

Current Rank	AR Type	Plan Paid	Specialty Plan Paid	Brand Plan Paid	Generic Plan Paid	Claims	Unique Members
1	AH503A	\$455,792	\$214,163	\$191,034	\$50,595	2,190	114
2	AH502A	\$149,434	\$78,214	\$48,448	\$22,772	1,359	138
3	AH503C	\$0	\$0	\$0	\$0	5	1
Total		\$605,226	\$292,377	\$239,481	\$73,368	3,554	253*

\*Total Unique Members are calculated across all claims for this slide's category for the requested time frame.